Patent Application
20230295573
The present invention relates to engineered neocartilage tissue compositions, e.g., tissue compositions produced by cells subjected to extensive passaging and rejuvenation, and includes methods for passaging cells that result in highly expanded and functional cells such as functional chondrocytes for neocartilage production. The present invention is not limited to chondrocytes or neocartilage constructs.
Human articular chondrocytes (hACs) are an autologous cell source used clinically to repair cartilage lesions. In addition to current surgical approaches, including chondroplasty, microfracture, mosaicplasty, and autologous chondrocyte implantation (ACI), a variety of tissue-engineered cartilage products derived from minimally expanded hACs (e.g., from Passages 1-3; P1-P3) has been introduced for clinical use. However, the limited cellularity in cartilage requires extensive passaging (e.g., beyond P3) to obtain sufficient cells for cell-based therapeutics. In addition, chondrocytes are prone to lose their chondrogenic phenotype during monolayer expansion, which impedes successful uses of hACs in tissue engineering applications. Strategies to retain chondrogenic potential of passaged hACs [e.g., conservative chondrogenic passaging; (CCP)] are necessary to advance their use for clinical products for cartilage repair and regeneration.
The effects of cell passaging on the phenotype changes of articular chondrocytes are well-known. Monolayer expansion of chondrocytes results in rapid de-differentiation, elevating type I collagen expression and increasing cell size toward a fibroblastic morphology. Moreover, cells from extensive cell passaging (e.g., Passage 5-8; P5-8) were not able to be restored and generate any cartilage-specific markers, and the expression of cartilage-specific matrix proteins such as aggrecan and type II collagen decrease in a passage number-dependent manner. While chondrocytes at P1 formed tissues with glycosaminoglycan (GAG) and type 11 collagen, cells at P5 no longer exhibited the chondrocytic morphology or produced cartilage-specific matrix components (e.g., GAG, type II collagen). Strategies to retain or improve the chondrogenic potential of passaged chondrocytes (e.g., various medium compositions and three-dimensional culture systems) have been introduced to overcome the limits resulting from passaging, but with conflicting and limited success, particularly for human-derived cells. Autologous chondrocytes at up to P3 have been used in tissue-engineered cartilage products for completed clinical trials. Despite these endeavors, it is still recognized that phenotypic changes in passaged chondrocytes hamper the clinical use of chondrocytes, particularly when even higher passage numbers are required due to cell scarcity.
The technique of rejuvenation, or culturing cells in three-dimensional aggregates prior to use, has been shown to facilitate the restoration of passaged chondrocytes using CCP. The rejuvenation process applied after CCP, cultured in the presence of transforming growth factor-beta 1 (TGF-β1), bone morphogenetic protein-2 (BMP-2), and growth differentiation factor-5 (GDF-5), either alone or in combination, promoted P2 hACs to express chondrogenic genes, such as Sox9, Aggrecan, and type II collagen. The combined treatment of the three factors led to the greatest upregulation of cartilage matrix genes, resulting in the formation of mechanically robust neocartilage. Applied to animal cells, the effect of rejuvenation was also shown to revert leporine chondrocytes at high passages back to a chondrogenic phenotype. The neocartilage formed by P7 leporine chondrocytes following rejuvenation exhibited functional properties that were either similar to or greater than the properties of neocartilage derived from cells at lower passages. This remarkable finding has the potential to improve, significantly, current therapies for cartilage repair with respect to use of autologous chondrocytes at higher passages. However, despite promising results regarding rejuvenation of animal cells, questions remain on whether the efficacy seen for highly passaged animal cells can be replicated using human cells. For human cells, the rejuvenation process has only been shown to be effective at producing functional neocartilage with P2 cells.
The functional properties of tissue-engineered cartilage using minimally-passaged cells can be improved with exogenous stimuli, such as TGF-β1, chondroitinase-ABC (c-ABC), and lysyl oxidase-like 2 (LOXL2) (termed “TCL treatment”). TGF-β1 is a well-known factor to induce chondrogenesis and increase functional properties of engineered neocartilage. c-ABC, an enzyme that degrades GAG (i.e., chondroitin and dermatan sulfate), has emerged as a unique factor to increase collagen content and to enhance tensile properties of tissue-engineered cartilage. LOXL2 acts on lysine and hydroxylysine amino acids to create covalent pyridinoline (PYR) cross-links between collagen fibers. The exogenous application of LOXL2 yielded a remarkable improvement in tensile properties of engineered neocartilage with increased PYR crosslinking content. Applied in combination with TGF-β1 and c-ABC, engineered bovine neocartilage exhibited enhanced tensile properties and collagen content when compared to individual factors. Further, a combined treatment of TGF-β1, c-ABC, and LOXL2 was more effective in enhancing functional properties of engineered bovine neofibrocartilage when compared to other combinations.
Despite these endeavors for minimally passaged hACs, monolayer expansion of hACs through passaging leads to loss of chondrogenic potential, impeding their use for cartilage repair, particularly when high passage numbers are required due to cell scarcity.
The present invention features methods and systems to conserve the functional potential of highly expanded cells for cell and tissue engineering.
It was surprisingly discovered that multiply passaged hACs had efficacy for production of neocartilage. Despite the cells being passaged multiple times (e.g., beyond P3) and dissociated one or more times (e.g., two times, three times, etc.) using enzymes (e.g., trypsin; known to cause cell damage to the cell membrane) during conservative chondrogenic passaging (CCP) and rejuvenation, the multiply passaged and dissociated cartilage cells were found to have conserved functional properties similar to primary cells/minimally passaged cells and form functional neocartilage. The present invention 1) allows the conservation of multiply passaged hACs through conservative chondrogenic passaging (CCP) and rejuvenation, 2) produces human neocartilage using these passaged conserved hACs, and 3) augments the effects of the rejuvenation on passaged hACs by introducing a combination of TGF-β1, c-ABC, and LOXL2 (termed “TCL treatment”; chemical treatment). Surprisingly, conservation/rejuvenation, followed by TCL treatment, reverted hACs at higher passages to a chondrogenic phenotype, leading to formation of mechanically robust human neocartilage similar to those formed by hACs at lower passages. For example, as described in Example 1, rejuvenation, followed by TCL treatment, conserves chondrogenic phenotype of hACs used at higher passages and leads to formation of mechanically robust human neocartilage similar to that formed by hACs of lower passages.
These results were surprising because results are limited from most prior studies, which used minimally passaged cells (≥P3), chondrogenic medium containing only a single growth factor, or animal cells. For example, enhancement of chondrogenic potential of human cartilage cells was observed in minimally-passaged cells (e.g., passaged up to P2/P3) and rejuvenated in the presence of multiple growth factors or of animal cells passaged up to P3 and using a rejuvenation medium containing only a single growth factor. In addition, biochemical and mechanical properties were enhanced in neocartilage constructs when P2-P7 expanded animal cells were used and exposed to a rejuvenation medium containing only a single growth factor.
These results were not predicted because prior studies attempting to restore chondrogenic potential using highly-passaged cells have failed. Results from previous studies using highly expanded chondrocytes showed that these chondrocytes in the tissue formed do not exhibit the chondrogenic phenotype, and the tissue formed itself does not exhibit cartilaginous tissue characteristics (e.g., biochemical and mechanical properties that are similar to those for native tissue). For example, cartilage formed in vivo using human articular cartilage-derived cells (HACSC) at high passages (e.g., up to 20 population doublings) typically displays fibrous tissue with type I collagen immunoreactivity, indicating that the tissue formed in vivo is not hyaline cartilage tissue. Another example is that late passage (P6; 12 population doublings) human mesenchymal stem cells (hMSCs) did not undergo chondrogenesis in monoculture with chondrogenic stimuli (e.g., TGF-β31) or in co-culture with articular chondrocytes (ACs), despite stimulating GAG accumulation. Although increased type II collagen content in expanded bovine synovium-derived stem cells occurred at P4 compared to P1, GAG content was decreased, and electric field cell migration was opposite at P4 compared to P1 despite using a chondrogenic media consisting of TGF-β1, a fibroblast growth factor (FGF), and a platelet-derived growth factor (PDGF) (TFP treatment) and micro-pellet three-dimensional culture. Thus, it is unclear whether or not cells of a certain species, passage, culture condition, or chemical treatment are preferentially more likely to adopt a phenotype favorable for cartilage matrix development.
The effect of combining rejuvenation and TCL treatment on engineering functional neocartilage has not been previously evaluated in either animal- or human-derived ACs at high passages. In addition, the effect of rejuvenation itself on engineering functional cartilage exhibited different characteristics between high passage leporine and human chondrocytes. Importantly, TCL treatment on engineered neofibrocartilage did not alter morphology of tissues formed using animal cells, although, as seen in
Therefore, it is surprising that the present invention produces mechanically robust human neocartilage similar to those formed by hACs at lower passages. The use of the rejuvenating medium conserves the chondrogenic phenotype of highly expanded human cartilage cells, and the tissue generated by these cells is functional (i.e., biochemical and mechanical properties are similar to native values).
The present invention features methods for conserving highly expanded cartilage cells to produce their original characteristics or conserving highly expanded cartilage cells to have characteristics that non-highly expanded cartilage cells possess. That includes, for example, highly expanded chondrocytes (e.g., human articular chondrocytes), having a particular function or potential such as the potential to produce neotissue. The expanded cartilage cells (e.g., chondrocytes) can be used to construct neotissue (e.g., neocartilage) that exhibit functional properties similar to native articular cartilage. The methods and systems feature a process (e.g., including CCP, rejuvenation, and chemical treatment such as TCL treatment) that forms functional human cartilage using cells that have been expanded, e.g., to 12.6×106 times or more, or through 11 passages or more. This enables a large quantity of engineered cartilage implants to be produced from a few cells.
The present invention features a method for conserving cartilage cells, expanded to high passages. These methods comprise: 1) expanding the cartilage cells to Passage N=5 (P5) and beyond by culturing the cells in monolayer; 2) subjecting expanded cells to dissociation and a three-dimensional environment; and 3) acquiring conserved cartilage cells by dissociating the cells from the three-dimensional environment.
In some embodiments, the conserved cartilage cells exhibit characteristics similar to or better than characteristics exhibited by cartilage cells at P0 (native state) or at Passage N-X, wherein N is the passage number, X is any integer between 1 and N.
The present invention further features a method for conserving human cartilage cells comprising: 1) conservative chondrogenic passaging (CCP) to Passage N=3 (P3) or greater, by culturing the human cartilage cells in monolayer in a CCP medium comprising one or more of a TGF-β superfamily protein, a fibroblast growth factor, and a mitogen (e.g., platelet-derived growth factor, PDGF; TFP treatment); 2) subjecting the expanded cells to dissociation and a three-dimensional environment in the presence of a rejuvenating medium comprising one or more of TGF-β superfamily protein, a growth differentiation factor, and bone morphogenetic protein; and 3) acquiring conserved cartilage cells by dissociating the cells from the three-dimensional environment.
In some embodiments, the method of CCP and rejuvenating cells can be repeated in different amounts of times, orders, and combinations. Non-limiting examples comprise: CCP, CCP, rejuvenation; rejuvenation, CCP, CCP; CCP, rejuvenation, CCP.
The present invention further features a method of forming a tissue derived from cartilage cells (e.g., human cartilage cells), expanded to high passages. The method comprising: 1) expanding the cells to Passage N=5 (P5) and beyond, by culturing the cells in monolayer; 2) subjecting the expanded cells to dissociation and a three-dimensional environment; and 3) forming a three-dimensional tissue using dissociated cells from the three-dimensional environment.
In some embodiments, the tissue formed from restored cartilage cells exhibits characteristics similar or better than characteristics exhibited by tissue formed by cartilage cells at P0 (native state) or at Passage N-X, wherein N is the passage number, X is any integer between 1 and N.
The present invention further features a method of forming a tissue derived from cartilage cells (e.g., human cartilage cells). The method comprises: 1) CCP to Passage N=3 (P3) or beyond, by culturing the cells in monolayer in a CCP medium comprising one or more of a TGF-β superfamily protein, a fibroblast growth factor, and a mitogen; and 2) subjecting the expanded cells to dissociation and a three-dimensional environment in the presence of a rejuvenating medium comprising one or more of TGF-β superfamily protein, a growth differentiation factor, and bone morphogenetic protein; and 3) forming a three-dimensional tissue using dissociated cells from the three-dimensional environment in the presence of chemical treatment for a period of time comprising of one or more TGF-β superfamily proteins, one or more proteoglycan degrading agents, and one or more cross-linking agents.
In some embodiments, the cells in the three-dimensional culture form neocartilage, which has mechanical properties similar to native articular cartilage. Forming the tissue in three-dimensional culture comprises fabricating the tissue with circular, square, rectangular, curved, or customized shapes.
In some embodiments, the resulting tissue can be used to treat chondral lesions, osteochondral lesions, and osteoarthritic conditions.
In appropriate circumstances, the methods of CCP and rejuvenating cells, and forming a tissue can be repeated in different amounts of times, orders, and combinations.
The present invention features an engineered neocartilage tissue composition comprising human costal cartilage-derived cells at passage 5 (P5) or greater, wherein the composition exhibits ≥50 kPa tensile Young's modulus.
The present invention also features an engineered neocartilage tissue composition comprising human costal cartilage-derived cells at passage 5 (P5) or greater, wherein the composition exhibits ≥50 kPa tensile Young's modulus, and the composition comprises ≥2% glycosaminoglycan per dry weight (GAG/DW) or ≥1% total collagen per dry weight (Col/DW).
The present invention also features an engineered neocartilage tissue composition comprising human costal cartilage-derived cells at passage 5 (P5) or greater, wherein the composition comprises ≥2% glycosaminoglycan per dry weight (GAG/DW) and ≥1% total collagen per dry weight (Col/DW), and exhibits ≥50 kPa tensile Young's modulus and ≥10 kPa ultimate tensile strength (UTS).
In some embodiments, the engineered neocartilage tissue composition is scaffold-free. In some embodiments, the human costal cartilage-derived cells comprise allogeneic cells sourced from human rib cartilage. In some embodiments, the human costal cartilage-derived cells comprise chondrocytes. In some embodiments, the human costal cartilage-derived cells comprise progenitor cells. In some embodiments, the human costal cartilage cells at passage 5 (P5) or greater are cells that have been subjected to aggregate rejuvenation, a self-assembling process, or a combination thereof. In some embodiments, the composition further comprises at least a second tissue composition stacked thereon.
The present invention also features an engineered neocartilage composition, made by a method comprising: culturing a population of cells derived from human costal cartilage at passage 0 (P0) or higher in monolayer in a medium comprising two or more of: transforming growth factor (TGF)-β superfamily proteins, fibroblast growth factors, and mitogens; and expanding said cells to passage 5 (P5) or beyond in said medium; subjecting the expanded cells from the previous step to dissociation and subsequent culture in a first three-dimensional, non-adherent environment in a medium comprising two or more of: transforming growth factor (TGF)-β proteins, growth differentiation factors, and bone morphogenetic proteins; and subjecting the cells from the previous step to dissociation and subsequent culture in a second three-dimensional, non-adherent environment for a period of time in a medium comprising: one or more of transforming growth factor (TGF)-β superfamily proteins, one or more of proteoglycan and/or glycosaminoglycan degrading agents, and one or more of collagen cross-linking agents, such that the cells form neocartilage.
In some embodiments, the neocartilage exhibits a tensile Young's modulus of 50 kPa. In some embodiments, the neocartilage comprises ≥2% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the neocartilage comprises ≥1% total collagen per dry weight (Col/DW. In some embodiments, the neocartilage exhibits an ultimate tensile strength of 210 kPa.
In some embodiments, the medium in the third step further comprises a cytoskeleton modifying agent, wherein the cytoskeleton modifying agent comprises cytochalasin D. In some embodiments, the method further comprises subjecting the neocartilage formed in the third step to a treatment comprising transforming growth factor (TGF)-β1, chondroitinase-ABC, lysyl oxidase-like 2, or a combination thereof. In some embodiments, the glycosaminoglycan degrading agent comprises chondroitinase-ABC or the collagen cross-linking agent comprises lysyl oxidase-like 2. In some embodiments, the neocartilage formed in the third step is combined with another tissue or a scaffold.
In some embodiments, the engineered neocartilage tissue composition is scaffold-free. In some embodiments, the cells derived from human costal cartilage comprise chondrocytes. In some embodiments, the cells derived from human costal cartilage comprise progenitor cells. In some embodiments, the cells from human costal cartilage are allogeneic cells. In some embodiments, the composition is configured for surgical implantation in a patient or used ex vivo. In some embodiments, the composition is configured to repair hyaline cartilage, fibrocartilage, or elastic cartilage. In some embodiments, the composition is configured to repair one or a combination of chondral lesions, osteochondral lesions, or osteoarthritic conditions. In some embodiments, the composition is configured to repair a temporomandibular joint (TMJ) disc complex or TMJ tissues. In some embodiments, the composition is configured to repair knee meniscus, nasal cartilages, facet cartilages, knee articular cartilages, ear cartilages, or a combination thereof.
Any feature or combination of features described herein are included within the scope of the present invention provided that the features included in any such combination are not mutually inconsistent as will be apparent from the context, this specification, and the knowledge of one of ordinary skill in the art. Additional advantages and aspects of the present invention are apparent in the following detailed description and claims.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The features and advantages of the present invention will become apparent from a consideration of the following detailed description presented in connection with the accompanying drawings in which:
The present invention features methods for restoring cartilage cells, expanded to high passages, P3 or greater. For example, highly expanded chondrocytes (e.g., human articular chondrocytes) can be used to construct neotissue (e.g., neocartilage) exhibiting functional properties similar to native articular cartilage. The methods and systems feature a process (e.g., CCP, rejuvenation, and TCL treatment) that forms functional, human cartilage using cells that have been expanded, e.g., to 12.6×106 times or more, or through 11 passages or more through conservative chondrogenic passaging (CCP). This enables a large quantity of engineered cartilage implants to be produced from few cells. Note the present invention is not limited to producing highly expanded chondrocytes or producing cells for human cartilage production. The present invention is also not limited to the number of passages described herein.
The methods of the present invention feature a combination of: 1) CCP), 2) rejuvenation, 3) tissue formation using different processes such as the self-assembling process, and 4) agents, including chemical, biophysical, mechanical, such as a regimen of optimized bioactive agents (e.g., TCL treatment) (
In some embodiments, the cartilage cells are human cells and may comprise chondrocytes, fibrochondrocytes, or combination thereof. The chondrocytes are derived from hyaline or elastic cartilage, including, but not limited, to all diarthrodial joints, ribs, nose, larynx, trachea, ear, and epiglottis. The fibrochondrocytes are derived from, but not limited to, the temporomandibular joint, intervertebral disc, meniscus, tendon, and ligament.
As a non-limiting example, cells are cultured (for CCP purposes) in monolayer in CCP medium. For appropriate circumstances, the CCP medium comprises one or more of: a TGF-β superfamily protein, an FGF, and a mitogen [e.g., media supplemented with TFP (TGF-β, FGF-2, PDGF, and/or the like, or combinations thereof, etc.)] to expand the cells up to P11.
The TGF-β superfamily protein in the CCP medium comprises one or more of, but not limited to: TGF-β1; TGF-β2; TGF-β3; TGF-β4; a GDF; a BMP; a glial-derived neurotrophic factor; NODAL; mullerian inhibiting hormone: or a combination thereof. Non-limiting examples of GDF comprise one or more of: GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-8, GDF-9, GDF-10, GDF-11, GDF-15. Non-limiting examples of BMP comprise one or more of: BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP8, BMP-10, BMP-11, BMP-15, or a combination thereof. Fibroblast growth factor examples comprise, but not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-16, FGF-17, FGF-18, FGF-19, FGF-20, FGF-21, FGF-22, FGF-23, or a combination thereof. Non-limiting examples of the rnitogen comprise PDGF-/PDGF-AA/-BB/-AB, chemical substances triggering mitosis through mitogen-activated protein kinase (MAPK), or a combination thereof.
For appropriate circumstances, the method of CCP comprises subjecting the cells in CCP medium containing epidermal growth factor (EGF), insulin-like growth factors (IGFs), superficial zone protein (SZP)/proteoglycan 4 (PRG4), or a combination thereof.
In some embodiments, the method of CCP comprises subjecting the cells in CCP medium containing proteoglycan molecules including, but not limited to, aggrecan, hyaluronan, chondroitin-4/−6 sulfate, keratan sulfate, dermatan sulfate, heparin, heparin sulfate, etc., or the medium containing collagen molecules including, but not limited, to collagen types 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 14, 16, 22, 27, or a combination thereof.
In some embodiments, the method of CCP comprises subjecting the cells to CCP medium containing matrix degrading enzymes, cytoskeleton modifying reagents, cross-linking agents, or a combination thereof (e.g., TCL treatment). The matrix degrading enzymes comprise one or more of, but not limited to, chondroitinase-ABC, trypsins, pepsins, papains, hyaluronidases, heparinases, keratinases, collagenases, or a combination thereof. The cytoskeleton modifying reagents comprise one or more of, but not limited to, cytochalasins and latrunculins. The cross-linking agents comprise one or more of, but not limited to, a lysyl oxidase protein such as LOXL1, LOXL2, LOXL3, LOXL4, etc.; other cross-linking enzymes/agents such as genipin, glutaraldehyde, etc.; other cross-linking enzymes/agents that yield pyridinoline cross-links; or a combination thereof.
Additional appropriate circumstances for methods of CCP include subjecting the cells to 1) hypoxic conditions or 2) mechanical stimulation. For example, the hypoxic conditions are derived physically or from chemical treatment to reach less than 21% oxygen. The chemical treatment comprises one or more of, but not limited to, desferrioxamine, cobalt, glucose oxidase (GOX)/catalase (CAT), or a combination thereof. Mechanical stimulation includes, but not limited to, fluid induced shear stress, hydrostatic pressure, or a combination thereof.
Conservative chondrogenic passaging for some circumstances involves enzymatic digestion, mechanical dissociation, or a combination thereof. The enzymatic digestion comprises, but not limited to, subjecting the passaged cells to proteolytic enzymes/matrix degrading enzymes such as trypsins, collagenases, or a combination thereof.
In some embodiments, the monolayer cells are cultured at a seeding density of 500,000 cells/cm2 or less, expanded 1.5×105 times or more, and expanded through 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 passages or more. A non-limiting example comprises cells being cultured at a seeding density of 25,000 cells/cm2 and expanded at least 1.5×105 times. Non-limiting examples also comprise expanding 0.9×106 or 1.5×106 times at P9 and 12.6×106 times at P11.
After repeated series of CCP, cells are dissociated from monolayer culture using enzymes into a cell suspension and subjected to three-dimensional environment in the presence of a rejuvenating medium. For example, the cells are cultured (for rejuvenation) in three dimensional suspensions (e.g., for one week) in the presence of a rejuvenation treatment before being enzymatically dissociated. The rejuvenation medium comprises one or more of a TGF-β superfamily proteins, a growth differentiation factor (GDF), and a BMP protein (e.g., TGF-β1, GDF-5, and/or BMP-2, and/or the like, or combinations thereof, etc.). Note the present invention is not limited to TGF-β1, GDF-5, and/or BMP-2. In some embodiments, the rejuvenation treatment comprises one or a combination of proteins from the TGF-beta superfamily [e.g., TGF-beta proteins (e.g., TGF-β1, TGF-β2, TGF-β3, TGF-β4, etc.), GDF (e.g., GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-8, GDF-9, GDF-10, GDF-11, GDF-15, or combination thereof), BMP (BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-10, BMP-11, BMP-15, or combination thereof), glial-derived neurotrophic factors, NODAL, and mullerian inhibiting hormone, etc.].
In some embodiments, subjecting the cells to the three-dimensional environment comprises a use of a medium containing epidermal growth factor (EGF), FGF-2, insulin-like growth factors (IGFs), superficial zone protein (SZP)/proteoglycan 4 (PRG4), or a combination thereof. For example, IGF-1 is used as an alternative to the TGF-beta superfamily protein, IGF-1 also may be used in combination with BMP. IGF has been shown to promote chondrocyte proliferation during chondrogenesis and is also involved in promoting the expression of cartilage-specific matrix. Another example of the method features systemic administration of compounds to increase cell viability and proliferation (e.g., EGF and/or FGF-2 and/or the like, or combinations thereof, etc.) in conjunction with the suspension culture.
Subjecting the cells to the three-dimensional environment can also comprise a use of medium containing 1) proteoglycan molecules or 2) matrix degrading enzymes, cytoskeleton modifying reagents, cross-linking agents, or a combination thereof. Proteoglycan molecules comprise, but not limited to, aggrecan, hyaluronan, chondroitin-4/−6 sulfate, keratan sulfate, dermatan sulfate, heparin, heparin sulfate, etc., or the medium containing collagen molecules including, but not limited to, collagen types 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 14, 16, 22, 27, or a combination thereof. Examples of matrix degrading enzymes comprise one or more of, but not limited to, chondroitinase-ABC, trypsins, pepsins, papains, hyaluronidases, heparinases, keratinases, collagenases, or a combination thereof. Non-limiting examples of cytoskeleton modifying reagents comprise one or more of cytochalasins and latrunculins. Examples of cross-linking agents comprise one or more of, but not limited to: a lysyl oxidase protein such as LOXL1, LOXL2, LOXL3, and LOXL4, etc.; other cross-linking enzymes/agents such as genipin, glutaraldehyde, etc.; other cross-linking enzymes/agents that yield pyridinoline cross-links; or a combination thereof.
In appropriate circumstances, culturing in the three-dimensional environment comprises subjecting the cells to 1) hypoxic conditions derived physically or from chemical treatment to reach less than 21% oxygen and/or mechanical stimulation. The chemical treatment comprises one or more of, but not limited to, desferrioxamine, cobalt, glucose oxidase (GOX)/catalase (CAT), or a combination thereof, Examples of mechanical stimulation comprise, but not limited to, fluid induced shear stress, hydrostatic pressure, or a combination thereof.
In some embodiments, the three-dimensional environment comprises ≥1) suspension culture at a seeding density of 100,000 cells/mi or more and 2) culturing the passaged cells for rejuvenation for 1-14 days. A non-limiting example comprises seeding suspension culture at 750,000 cells/ml and culturing for 14 days.
Subjecting cells in the three-dimensional environment also can comprise non-suspension culture, such as scaffold-free or scaffold-based three-dimensional culture, or a combination thereof. Examples of the scaffold-free three-dimensional culture comprise, but not limited to, self-assembly, pellet culture, micromass, hanging drop method, embryoid bodies, or a combination thereof. Non-limiting examples of the scaffold-based three-dimensional culture comprise gel, beads, sheet, freeze-dried materials, porous scaffolds, or a combination thereof. The composition of scaffolds is derived from natural materials, synthetic materials, or modified natural materials, but not limited to, collagens, silk, chitosan, poly(lactic acid), poly(ethylene glycol), or a combination thereof.
In some embodiments, the method further comprises dissociating the three-dimensional cultured cells via 1) enzymatic digestion or 2) mechanical dissociation. Examples of the enzymatic digestion comprise subjecting the cells to proteolytic enzymes/matrix degrading enzymes such as trypsin, collagenase, or a combination thereof, Therefore, the matrices the cells have made up to this point are digested and removed. In some embodiments, the dissociated cells can be used for cell therapies or forming a tissue to treat cartilage defects. A non-limiting example comprises formation of neocartilage that had mechanical properties similar to native articular cartilage.
The suspended cells are then seeded anew in three-dimensional culture to form cartilaginous tissue (for the self-assembling process). In some embodiments, the period of time of culturing in the three-dimensional culture is at least 10 days.
In some embodiments, the method of forming a tissue comprises dissociating the three-dimensional cultured cells and seeding the cells in a three-dimensional culture.
A non-limiting example of forming the tissue in three-dimensional culture comprises scaffold-free culture systems, which comprise, but not limited to, self-assembly, pellet culture (aggregate formation), micromass, hanging drop method, embryoid bodies, or a combination thereof.
In appropriate circumstances, forming a tissue in three-dimensional culture comprises scaffold-based culture systems, which comprise, but not limited to, gel, beads, sheet, freeze-dried materials, porous scaffolds, or a combination thereof. The composition of scaffold are derived from natural materials, synthetic materials, or modified natural materials, but not limited to, collagens, silk, chitosan, poly(lactic acid), poly(ethylene glycol), or a combination thereof.
In some embodiments, forming a tissue in three-dimensional culture comprises treating the three-dimensional culture of the tissue with a chemical treatment for a period of time. The chemical treatment comprises one or a combination of one or more TGF-β superfamily proteins, one or more proteoglycan degrading agents, and one or more cross-linking agents (TCL treatment). Non-limiting examples of the chemical treatment comprise treating with the TGF-β superfamily protein for at least 10 days, treating with the proteoglycan degrading agent for at least 30 minutes on any day or days after day 4, and treating with the cross-linking agent for any duration after day 7. A specific example comprises treating the tissue with TGF-β1 throughout the culture, proteoglycan degrading agent for 4 hrs at day 7, and cross-linking agent from day 7 to 21.
Non-limiting examples of the TGF-β superfamily protein comprise one or more of: TGF-β1, TGF-β2, TGF-β3, TGF-β4, a GDF, an BMP, a glial-derived neurotrophic factor, NODAL, mullerian inhibiting hormone, or a combination thereof. Non-limiting examples of GDF comprise one or more of: GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-8, GDF-9, GDF-10, GDF-11, GDF-15, or a combination thereof. Non-limiting examples of BMP comprise one or more of: BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP8, BMP-10, BMP-11, BMP-15, or a combination thereof. Examples of the proteoglycan degrading agents comprise, but not limited to, chondroitinase-ABC, trypsins, pepsins, papains, hyaluronidases, heparinases, keratinases, collagenases, or a combination thereof. Examples of the cross-linking agents comprise, but not limited to, a lysyl oxidase protein such as LOXL1, LOXL2, LOXL3, and LOXL4; other cross-linking enzymes/agents such as genipin, glutaraldehyde, etc.; other cross-linking enzymes/agents that yield pyridinoline cross-links; or a combination thereof.
In some embodiments, forming the tissue in three-dimensional culture comprises subjecting the tissue to other growth factors, including, but not limited to, EGF, FGF-2, IGF, superficial zone protein (SZP)/proteoglycan 4 (PRG4), or a combination thereof. Forming the tissue in three-dimensional culture also can comprise subjecting the tissues to proteoglycan molecules including, but not limited to, aggrecan, hyaluronan, chondroitin-4/−6 sulfate, keratan sulfate, dermatan sulfate, heparin, heparin sulfate, etc., or to collagen molecules including, but not limited to, collagen types 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 14, 16, 22, 27, or a combination thereof.
In some embodiments, forming the tissue in three-dimensional culture comprises subjecting the tissue to 1) hypoxic conditions or 2) mechanical stimulation. The hypoxic conditions are derived physically or from chemical treatment to reach less than 21% oxygen. The chemical treatment comprises one or more of, but not limited to, desferrioxamine, cobalt, glucose oxidase (GOX)/catalase (CAT), or a combination thereof. Methods of mechanical stimulation comprise, but not limited to, fluid induced shear stress, compressive stress, tensile stress, hydrostatic pressure, or a combination of thereof.
In some embodiments, chemical treatments are applied during culture to obtain the desired tissue qualities (e.g., TCL treatment as described in Example 1). In some embodiments, the cells generated by the procedures described above may be used for generating mechanically stimulated cartilage implants. In some embodiments, the TCL treatment comprises one or a combination of a TGF-beta superfamily protein (TGF-β1, TGF-β2, TGF-β3, TGF-β4, etc.), chondroitinase-ABC, and/or a lysyl oxidase protein (e.g., LOXL2, LOXL1, LOXL3, LOXL4, etc.). In some embodiments, other proteoglycan degrading enzymes/agents (e.g., trypsin, pepsin, papain, etc.) and cross-linking enzymes/agents (e.g., genipin, etc.) may be used as alternatives for c-ABC and LOXL2, respectively. For alternatives to TGF-beta, other growth factors known to produce extracellular matrix (ECM) can be used such as, for example, other members of TGF-beta superfamily, IGFs, BMPs, etc.
In appropriate circumstances, cells are combined with non-chondrocytic cells (e.g., skin-derived stem cells) to further reduce the number of donor chondrocytes needed.
As previously discussed, the present invention is not limited to cartilage cells. For example, the processing methods described can also be applied to cells derived from osteoarthritic tissues to produce functional cartilage implants. The methods of the present invention may be applied to fibrochondrocytes and/or human adult mesenchymal stem cells (e.g., derived from various locations including, but not limited, to bone marrow, adipose tissue, and skin) to differentiate into chondrocytes and produce functional cartilage implants.
The present invention further features methods for producing cartilaginous implants derived from human chondrocytes at P2, P3, P4, P5, P6, P7, P8, P9, P10, P11, or more that exhibit functional properties similar to native articular cartilage. The cartilaginous implants may be for replacement of the entire knee (e.g., for numerous patients), e.g., for patients suffering from trauma and/or osteoarthritic disease, etc.
Calculations have estimated the number of cells that can be generated from donor chondrocytes. A 1 mm3 biopsy provides approximately 10,000 cells (10,000 cells/mm3 biopsy). Using the methods of the present invention, one donor chondrocyte can be expanded to 1.5×106 cells with 9 passages. Thus, a 1 mm3 biopsy can yield 1.5×1010 cells. Considering the approximate volume of a human knee is 20,000 mm3 and 10,000 cells/mm3 are needed for replacement, the 1.5×1010 cells of the 1 mm3 biopsy can provide enough coverage for 75 knees. Stated differently, the 1.5×1010 cells of the 1 mm3 biopsy can cover a volume of 1.5×106 min. This could be 1500 different 1,000 mm3 sized repairs. Again, for one knee (see
Table 1 provides a summary of characteristics for cells and tissues produced from the methods featured in the present invention. In some embodiments, the methods produce functional cartilage cells and tissues that have characteristics similar to or better than characteristics exhibited by native state cells (Passage P=0) or at Passage N-X, wherein N is the passage number, X is any integer between 1 and N. For example, when N is 3 and X is 3, then N-X is 0, indicating that the cartilage cells exhibit features similar to native state of P0. As stated above, Passage N-X can produce cartilage cells and tissues that have characteristics better than the P0, native state.
The present invention also features a method of fabricating a tissue in three-dimensional culture comprising forming the tissue to integrate into another tissue. Non-limiting examples comprise: 1) integration of cartilage to cartilage; 2) integration of cartilage to bone, and 3) integration of ligament to bone.
The present invention also features a method of conserving cartilage cells, expanded to greater than P1 but limited to P4; these are the passage numbers most commonly used for current therapies. For example, the method comprises CCP by culturing the cells in monolayer in a CCP medium and subjecting the passaged cells to a three-dimensional environment in a rejuvenating medium. In some embodiments, the CCP medium comprises one or more of: a TGF-β superfamily protein, an FGF, and a mitogen, and the rejuvenating medium comprises one or more of: a TGF-β superfamily protein, a GDF, and an BMP.
The present invention also features a method of forming a tissue derived from cartilage cells, expanded to greater than P1 but limited to P4; these are the passage numbers most commonly used for current therapies. For example, the method comprises CCP cells in monolayer in a CCP medium, subjecting the passaged cells to a three-dimensional environment in a rejuvenating medium, and forming a tissue in presence of chemical treatment for a period of time. The CCP medium comprises one or more of: a TGF-β superfamily protein, an FGF, and a mitogen. The rejuvenating medium comprises of one or more of: a TGF-β superfamily protein, a GDF, and an BMP.
The present invention is not limited to chondrocytes and neocartilage construct production, and the present invention is not limited to the methods and compositions of Example 1 (e.g., the composition of medium for rejuvenation, the composition of TCL treatment of Example 1, etc.). The present invention also is not limited to the number of passages described herein.
These methods also can be utilized in other cell types such as human adult mesenchymal stem cells, human embryonic stem cells, genetically modified cells, or a combination thereof. Human adult mesenchymal stem cells are derived from various locations including, but not limited to, bone marrow, adipose tissue, and skin. The genetically modified cells comprise induced pluripotent stem cells (iPSCs).
These methods also can be utilized in cell types derived from other tissue types such as musculoskeletal tissues, cardiovascular tissue, neurosensory tissues, and liver tissue.
The present invention features engineered neocartilage tissue compositions. The compositions comprise cells sourced from human rib cartilage (e.g., costal cartilage cells, progenitor cells, etc.) that have been passaged at least five times, e.g., cells at passage 5 (P5) or greater. As is described herein, the cells may have been subjected to aggregate rejuvenation and a self-assembling process.
In some embodiments, the engineered neocartilage tissue composition comprises ≥2% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥3% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥4% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥25% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥6% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥7% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥8% glycosaminoglycan per dry weight (GAG/OW). In some embodiments, the engineered neocartilage tissue composition comprises ≥9% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥10% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥20% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥25% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥30% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥40% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥50% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥60% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥75% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥80% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥90% glycosaminoglycan per dry weight (GAG/DW).
In some embodiments, the engineered neocartilage tissue composition comprises 2-5% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-5% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 5-10% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-15% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 10-20% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 2-20% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 2-25% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-20% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-25% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-20% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-25% glycosaminoglycan per dry weight (GAG/DW).
In some embodiments, the engineered neocartilage tissue composition comprises ≥1% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥2% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥3% total collagen per dry weight (Col/DW), In some embodiments, the engineered neocartilage tissue composition comprises ≥4% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥5% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥6% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥7% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥8% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥9% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥10% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥20% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥25% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥30% total collagen per dry weight (Col/DW)). In some embodiments, the engineered neocartilage tissue composition comprises ≥40% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥250% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥60% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥75% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥80% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises ≥90% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 2-5% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-5% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 5-10% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-15% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 10-20% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 2-20% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 2-25% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-20% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 4-25% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-20% total collagen per dry weight (Col/DW). In some embodiments, the engineered neocartilage tissue composition comprises 8-25% total collagen per dry weight (Col/DW).
In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥50 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥100 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥200 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥250 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥500 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥750 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥1,000 kPa (1 MPa). In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus ≥10 MPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus of at least 100 MPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 50 kPa to 100 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 50 kPa to 250 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 100 kPa to 250 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 50 kPa to 500 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 100 kPa to 500 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 50 kPa to 1,000 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 250 kPa to 1,000 kPa. In some embodiments, the engineered neocartilage tissue composition has a tensile Young's modulus from 500 kPa to 1,000 kPa.
In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥10 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥20 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥50 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥75 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥100 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥250 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥500 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥1,000 kPa (1 MPa). In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) ≥10 MPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) of at least 100 MPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 10 kPa to 25 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 25 kPa to 50 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 50 kPa to 100 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 10 kPa to 100 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 100 kPa to 250 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 10 kPa to 250 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) from 100 kPa to 500 kPa. In some embodiments, the engineered neocartilage tissue composition has an ultimate tensile strength (UTS) greater than 500 kPa.
The neocartilage tissue compositions described herein may comprise allogeneic cells sourced from human rib cartilage. As used herein, the term “allogeneic” refers to cells of the same species that are genetically different from the cells being compared.
One of the unique and inventive technical features of the present invention is the use of allogeneic cells (e.g., allogeneic approaches). Without wishing to limit the invention to any theory or mechanism, it is believed that the use of allogeneic approaches advantageously do not rely on the quality of the patient's own cartilage. By using an allogeneic approach, a surgeon is not forced to use a patient's own tissue, thus, eliminating the limitation of a patient having poor quality donor tissue. Additionally, there is no donor site morbidity, because a donor tissue harvest site in the patient is not needed if an allogeneic approach is used. Contrastingly, autologous approaches require tissue harvest from the patient.
Furthermore, allogeneic approaches enhance product consistency and enable an off-the-shelf approach to patients in a shortened timeframe, which reduce manufacturing costs. Lastly, allogeneic tissues can be of greater availability.
The engineered neocartilage tissue compositions of the present invention are configured to be used for the repair of a tissue defect; however the present invention is not limited to these particular applications. In some embodiments, the tissue compositions are applied to the target tissue directly. In some embodiments, the tissue composition may be stacked on a second (or multiple) other engineered neocartilage tissue compositions. In some embodiments, the engineered neocartilage tissue composition is applied to a scaffold or other tissue. Non-limiting examples of other tissues the engineered neocartilage tissue composition may be applied to or combined with include: bone, meniscus, tendon, ligament, allografts, autografts, and/or xenografts.
The present invention features an engineered neocartilage tissue composition, made by a method comprising: a) culturing a population of cells sourced from human rib cartilage at passage 0 (P0) or higher in monolayer in a medium comprising two or more of: a transforming growth factor (TGF)-β superfamily protein, a fibroblast growth factor, and a mitogen; and expanding said cells to passage 5 (P5) or beyond in said medium, b) subjecting the expanded cells from (a) to dissociation and subsequent culture a first three-dimensional environment in a medium comprising two or more of: a transforming growth factor (TGF)-β superfamily protein, a growth differentiation factor, and a bone morphogenetic protein; and c) subjecting the human cartilage cells from (b) to dissociation and subsequent culture in a second three-dimensional environment for a period of time in a medium comprising: a transforming growth factor (TGF)-β superfamily protein, a proteoglycan and/or glycosaminoglycan degrading agent, and a collagen cross-linking agent. In some embodiments, the resulting neocartilage comprises ≥2% glycosaminoglycan per dry weight (GAG/DW) and ≥1% total collagen per dry weight (Col/DW). In some embodiments, the resulting neocartilage exhibits ≥50 kPa tensile Young's modulus and ≥10 kPa ultimate tensile strength. The resulting neocartilage comprises ≥4% glycosaminoglycan per dry weight (GAG/DW). The resulting neocartilage comprises ≥8% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the resulting neocartilage comprises ≥2% total collagen per dry weight (Col/DW). In some embodiments, the resulting neocartilage comprises ≥4% total collagen per dry weight (Col/DW). In some embodiments, the resulting neocartilage exhibits ≥100 kPa tensile Young's modulus and ≥50 kPa ultimate tensile strength. In some embodiments, the resulting neocartilage exhibits ≥200 kPa tensile Young's modulus and ≥100 kPa ultimate tensile strength.
The first three-dimensional environment and the second three-dimensional environment may comprise three-dimensional, non-adherent environments. In some embodiments, the medium from (c) further comprises a cytoskeleton modifying agent, wherein the cytoskeleton modifying agent comprises cytochalasin D. In some embodiments, the method further comprises subjecting the neocartilage formed from (c) to a treatment comprising chondroitinase-ABC, lysyl oxidase-like 2, cytochalasin D, or a combination thereof.
The present invention features a method of repairing a cartilage lesion. The method may comprise administering a neocartilage tissue composition as described herein to the cartilage lesion. The method may further comprise administering a means to adhere the composition to the lesion.
In some embodiments, adhering and/or anchoring of the tissue compositions to the surrounding tissue (e.g., defect) may feature the use of compositions such as, but not limited to, a fibrin sealant, sutures, pins, darts, anchors, bone anchors, or a combination thereof. In other embodiments, the means to adhere comprises the use of a melting agent and/or a melding agent as taught in U.S. patent application Ser. No. 17/368,394 filed Jul. 6, 2021, and entitled “Melt-and-meld approach to repair tissue defects,” incorporated herein by reference in its entirety for all purposes. As a non-limiting example, melting and melding the defect may include the use of melting agents that comprise chemicals and/or enzymes that help to melt a tissue matrix, wherein the melting agents comprise proteases or other ECM-degrading enzymes, chaotropes, or solvents including dispase, pepsin, elastase, hyaluronidase, aggrecanase, matrix metalloproteinases (MMPs), chondroitinase-ABC, trypsin, collagenase, guanidinium chloride, sodium dodecyl sulfate (SDS), or a combination thereof. In some embodiments, the melting agent is heat and/or a laser that helps to melt a tissue matrix. The melding agents may contain enzymes, chemicals, or growth factors that are capable of catalyzing the formation of macromolecules, forming macromolecules, or stimulating the formation of macromolecules, such as cross-links within tissue, wherein the melding agents comprise the family of lysyl oxidase or lysyl oxidase-like proteins, transglutaminase, riboflavin, vitamin B12, genipin, a transforming growth factor (TGF), growth differentiation factor (GDF), bone morphogenetic protein (BMP), fibroblast growth factor (FGF), epidermal growth factor (EGF), insulin-like growth factor (IGF), or a combination thereof.
The tissue compositions herein may be configured for surgical implantation in a patient or used ex vivo. The tissue compositions may be configured to be applied to a variety of tissues and for a variety of applications, including, but not limited to, the repair of hyaline cartilage, fibrocartilage, elastic cartilage, chondral lesions, osteochondral lesions, osteoarthritic conditions, temporomandibular joint (TMJ) disc complex, temporomandibular joint (TMJ) tissues, knee meniscus, nasal cartilages, facet cartilages, knee articular cartilage, ear cartilage, or a combination thereof.
As such, the present invention also features a method of repairing or ameliorating a temporomandibular joint (TMJ) disc complex or tissue; a method of repairing or ameliorating hyaline cartilage, fibrocartilage, or elastic cartilage; a method of repairing or ameliorating chondral lesions, osteochondral lesions, or osteoarthritic conditions; a method of repairing or ameliorating a knee meniscus; and a method of repairing or ameliorating defects in nasal cartilages, facet cartilages, knee articular cartilage, or ear cartilage. The methods may feature administering a neocartilage tissue composition as described herein to the target tissue, e.g., a TMJ disc complex or tissue. In some embodiments, the composition is configured to overlap with the native tissue, e.g., in the case of a TMJ disc complex tissue repair. In some embodiments, the composition is configured such that it does not overlap with the native tissue, e.g., for knee cartilage repair.
Additionally, the present invention may feature a method of repairing a knee cartilage lesion (e.g., a lesion in knee articular cartilage and/or a knee meniscus). The method comprises administering a neocartilage tissue composition as described herein to the knee cartilage lesion.
The following are non-limiting examples of the present invention. It is to be understood that said examples are not intended to limit the present invention in any way. Equivalents or substitutes are within the scope of the present invention.
It was surprisingly found that CCP and rejuvenation with subsequent TCL treatment revert hACs at higher passages (≥P3) to a chondrogenic phenotype, leading to formation of mechanically robust human neocartilage similar to those formed by hACs at lower passages.
Example 1 describes the restoration of hACs passaged up to P11 and the efficacy of a combined treatment of TGF-β1 (T), chondroitinase-ABC (C), and lysyl oxidase-like 2 (L) (termed “TCL treatment”) on further improving functional properties (e.g., augmenting effects of rejuvenation) of engineered human neocartilage as a function of passage number. The present invention is not limited to the methods, systems, compositions, and treatments described herein.
For reference, hACs are an autologous cell source used clinically to repair cartilage lesions. In addition to current surgical approaches, including chondroplasty, microfracture, mosaicplasty, and autologous chondrocyte implantation (ACI), a variety of tissue-engineered cartilage products derived from expanded hACs have been introduced for clinical use. Limited cellularity in cartilage requires passaging to obtain sufficient cells for cell-based therapeutics. However, chondrocytes are prone to lose their chondrogenic phenotype during monolayer expansion, which impedes successful uses of hACs in tissue engineering applications. For example, monolayer expansion of chondrocytes results in rapid de-differentiation, elevating type I collagen expression and increasing cell size toward a fibroblastic morphology. Moreover, cells from extensive cell passaging (e.g., passage 5-8 or P5-8) alone are currently not able to redifferentiate and generate any cartilage-specific markers. Previous studies showed decreases in expression of cartilage-specific matrix proteins such as aggrecan and type II collagen in a passage number-dependent manner. While chondrocytes at P1 formed tissues with GAG and type 11 collagen, cells at P5 no longer exhibited the chondrocytic morphology or produced cartilage-specific matrix components.
In Example 1, the scaffold-free, self-assembling process (that generates mechanically robust neocartilage) was used to form human neocartilage using cells from a 43 year-old male. Example 1 describes that CCP, and rejuvenation enhanced GAG content and type II collagen staining at all passages and also flattened constructs up to P7 with chondrogenic phenotype present. Addition of TCL treatment extended chondrogenic phenotype to P9. For both P7 and P9 constructs, TCL treatment significantly enhanced GAG content by 4.5-fold and type 11 collagen staining. Also, TCL treatment resulted in human neocartilage constructs, derived from high passages (e.g., P7 and P9), displaying mechanical properties similar to those derived from low passages (e.g., P3 and P5), The efficacy of CCP, rejuvenation, and TCL treatment on engineering functional neocartilage derived from cells of high passages was also shown using a different donor (a 34 year-old male); human neocartilage derived from P7 and P11 cells exhibited chondrogenic phenotype and mechanical properties similar to neocartilage derived from P3 cells. These data suggest that CCP and rejuvenation followed by TCL treatment may be a viable new strategy to generate functional human neocartilage using extensively passaged cells (e.g., cell doubling number from 4.5 at P2 to 23.6 at P11, see
Human articular chondrocyte isolation and CCP: Chondrocytes were isolated from human articular cartilage without signs of pathology, derived from a 43 year-old male. For a repeated study, chondrocytes derived from a 34 year-old male were used. Minced cartilage was digested in 0.2% collagenase type II (Worthington, Lakewood, NJ) solution including 3% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA) for 18 hrs at 37° C., followed by filtration through a 70 μm strainer. Isolated cells were counted, resuspended in freezing medium consisting of 90% FBS and 10% dimethyl sulfoxide (DMSO), and stored in liquid nitrogen until use. To obtain higher numbers of cells through cell passaging, CCP was applied. Briefly, hACs were seeded at a cell density of 25,000 cells/cm2 and expanded in chemically defined medium (CDM) (DMEM with high glucose/GlutaMAX™, 1% penicillin-streptomycin-fungizone (P/S/F), 1% non-essential amino acids (Gibco), 1% ITS+ premix (BD Biosciences), 50 μg/ml ascorbate-2-phosphate, 40 μg/ml L-proline, 100 μg/ml sodium pyruvate, and 100 nM dexamethasone), supplemented with 2% FBS, 1 ng/ml TGF-β1 (Peprotech, Rocky Hills, NJ), 5 ng/ml bFGF (Peprotech), and 10 ng/ml PDGF (Peprotech). Cells were passaged using 0.05% trypsin-EDTA (Gibco), followed by 0.2% collagenase type II solution containing 3% FBS, and frozen at P2, P4, P6, and P8 in liquid nitrogen until use. To examine the effects of rejuvenation and TCL, after thawing, cells underwent one more passage, leading to P3, P5, P7, and P9; cells then underwent self-assembly without rejuvenation (Ctrl), or rejuvenation followed by self-assembly (Rej). For the repeated study, cells frozen at P2, P6, and P10 were processed, as described above, to yield self-assembled constructs. The following formulae were used: cell doubling number=log(expansion factor)/log(2); expansion factor=final cell number/initial cell number.
The rejuvenation process: Cells at P3, P5, P7, and P9 were seeded at a cell density of 750,000 cells per ml in 1% agarose-coated plates for rejuvenation and maintained in CDM supplemented with 10 ng/ml TGF-β1, 100 ng/ml GDF-5, and 100 ng/ml BMP-2 for 7 days. After 7 days of culture, aggregates were digested and dissociated using 0.05% trypsin-EDTA, followed by 0.2% collagenase type II solution containing 3% FBS. After filtering, the resulting cells were seeded. For the repeated study, cell rejuvenation at P3, P7, and P11 was performed as above.
Neocartilage self-assembly: Neocartilage formation was performed through the self-assembling process as previously described. Briefly, 2% agarose solution was added in a 48-well plate into which a custom-made stainless steel mold with 5 mm diameter cylindrical prongs was immersed. After allowing the agarose to solidify, the well plates were washed with a washing medium consisting of DMEM with high glucose/GlutaMAX™ containing 1% P/S/F at least twice prior to cell seeding. Suspended in 100 μl of CDM supplemented with 200 units/nil hyaluronidase type I-S from bovine testes (Sigma Aldrich, St. Louis, MO) and 2 μM cytochalasin D (Enzo life Sciences, Farmingdale NY), 2×106 hACs from P3, P5, P7, and P9 with or without rejuvenation were seeded in each well. After 4 hrs of seeding, an additional 400 μl of CDM supplemented with 2 μM cytochalasin D was added to the wells. Medium was exchanged every 24 hrs, and cells were treated with 2 μM cytochalasin D for the first 72 hrs. After neocartilage constructs were unconfined from the agarose wells, medium was exchanged every other day. For the repeated study, cells at P3, P7, and P11 were seeded to form neocartilage constructs as above.
TCL treatment: For the control group, constructs were maintained in CDM. For the TCL-treated group, constructs were maintained in CDM, supplemented with 10 ng/ml TGF-β1 for the full culture duration. At t=7d, constructs were treated with 2 unit/ml of c-ABC (Sigma Aldrich) for 4 hrs at 37° C., followed by 1 mM zinc sulfate to stop the reaction for 10 min at 37° C. From t=7-21d, constructs were treated with 0.15 μg/ml of LOXL2 (SignalChem, Richmond, BC, Canada), supplemented with 0.146 mg/ml hydroxylysine and 1.6 μg/ml copper sulfate.
Mechanical testing and biochemical evaluation: Constructs were collected at 5 weeks for mechanical and biochemical evaluation. For compressive mechanical testing, samples were preconditioned with 15 cycles at 5% compressive strain. Incremental stress-relaxation was performed at a strain rate of 1% sample height per second; samples held at 10% strain were allowed to equilibrate, then strained to 20% with collection of force and displacement data. Relaxation modulus (Er), and instantaneous modulus (Ei) were calculated using a standard linear solid model. For tensile testing, samples were strained at a constant rate of 1% per second using a TestResource 840L. Young's modulus (EY) and ultimate tensile strength (UTS) were calculated using a custom MATLAB program. For biochemical assays, wet and dry weights of samples were measured before and after constructs were lyophilized. The lyophilized samples were digested in 125 μg/ml papain (Sigma Aldrich) in 50 mM phosphate buffer containing 2 mM N-acetyl cysteine (Sigma Aldrich) and 2 mM EDTA for 18 hrs at 60° C. GAG content was quantified using a Blyscan Glycosaminoglycan Assay kit (Biocolor, Newtownabbey, Northern Ireland). Total collagen content was assessed using a modified chloramine-T hydroxyproline assay that used hydrochloric acid instead of perchloric acid and a SIRCOL collagen standard (Accurate Chemical and Scientific Corp., Westbury, NY).
Histology and immunohistochemistry: Samples were fixed in 10% neutral-buffered formalin for histological assessment. Fixed samples were paraffin-embedded and sectioned at 5 μm. Sections were stained with hematoxylin and eosin (H&E); safranin-O and fast green; or picrosirius red using standard protocols. Immunohistochemistry (IHC) was used to detect collagen I and II expression using Vectastain ABC and DAB substrate kits (Vector Laboratories, Inc., Burlingame, CA). For primary antibodies, rabbit anti-type I collagen at a dilution of 1:500 (Abcam, Cambridge, MA) and rabbit anti-type II collagen (Abcam) at a dilution of 1:300 were used to detect type I and II collagen, respectively.
Statistics: All data are shown in mean±SD. Statistical differences among conditions were analyzed using one-way ANOVA with Tukey's post hoc test (p<0.05) (JMP12). Statistically significant differences are shown by bars not sharing the same letter.
Results: hAC CCP metrics: The metrics of hAC CCP in monolayer—initial seeding density, days in culture, final cell density, expansion factor, doubling time, cumulative expansion factor, and cumulative cell doubling number—are shown in
Gross morphological and histological evaluation of hAC neocartilage: hAC neocartilage exhibited distinctively different gross morphologies at each passage (
Addition of TCL treatment following CCP, and rejuvenation yielded more opaque morphologies in P3 and P5 constructs, when compared to constructs without TCL treatment. TCL treatment allowed P7 and P9 hACs to form flat constructs (
Differences in histological appearance were observed among groups with different passage numbers (
Biochemical and mechanical properties of hAC neocartilage: Treatment with CCP and rejuvenation, with or without being followed by TCL treatment, exhibited a range of enhancement in biochemical and mechanical properties of hAC neocartilage at different passages (
Mechanically, control hAC neocartilage constructs were not testable for compression and tension at any passage (
Example 1 shows that TCL treatment, applied to neocartilage formed using cells that had undergone CCP and rejuvenation, can be used to enhance functional properties of hAC neocartilage with high passage numbers. CCP and rejuvenation treatment elicited significant changes in construct and cell morphologies, exhibiting flattened constructs up to P7 with chondrogenic phenotype present. The addition of TCL treatment following CCP, and rejuvenation generated P9 constructs with flat construct morphology and cells in lacunae. Notably, at P7 and P9, TCL treatment yielded human neocartilage with functional properties similar to those derived from P3 and P5 cells, as demonstrated by GAG and type II collagen staining and by compressive and tensile properties. In the repeated study, CCP and rejuvenation followed by TCL treatment generated P11 constructs with flat construct morphology and cells in lacunae. Furthermore, the P11 constructs displayed similar biochemical and mechanical properties as constructs derived from P3 and P7 cells. Even with extensive passages, a combination of CCP, rejuvenation, and TCL treatment yielded neocartilage with functional properties similar to those of neocartilage derived from low passages.
Example 2 describes the neocartilage compositions and method of producing and using said compositions. The engineered neocartilage comprises high-passage, juvenile, allogeneic cultured cells derived from costal (rib) cartilage and their endogenously produced matrix indicated for the surgical repair of symptomatic defects in the TMJ disc complex. The present invention is not limited to the methods, systems, compositions, and treatments described herein.
1. Cell isolation and purification: Human cells (e.g., human cartilage cells, etc.) are obtained from costal cartilage sources. The whole costal cartilage tissue is dissected to remove muscle, adipose tissue, and perichondrium so that only cartilage remains. The harvested costal cartilage is dissected further into small pieces. The pieces of costal cartilage are enzymatically digested with pronase, followed by collagenase, to obtain a single-cell suspension. The isolated cells are further purified with a hypotonic buffer (ammonium chloride, potassium bicarbonate, and EDTA tetrasodium salt) to yield cell populations free of cellular detractors and undesired cells.
2. Cell expansion: The isolated, purified human costal cells from step 1 are serially expanded to passage N=5 (P5) or beyond in a chemically defined medium designed to preserve chondrogenic characteristics of the cells throughout passaging, e.g., CCP medium. In some embodiments, the medium comprises glucose, insulin, human transferrin, selenous acid, non-essential amino acids, sodium pyruvate, ascorbate-2-phosphate, L-proline, dexamethasone, fetal bovine serum, and growth factors (TGF-β1, bFGF, and PDGF). Human costal chondrocytes are grown in a monolayer to reach 90-95% confluency at each passage.
3. Cell rejuvenation: The expanded cells from step 2 are then placed into an aggregate culture for rejuvenation. Since chondrocytes rapidly de-differentiate during two-dimensional monolayer culture, this step is necessary to revert the cells back to a chondrogenic phenotype. This culture step, termed “aggregate rejuvenation,” occurs in a three-dimensional suspension culture in a medium. In some embodiments, the medium comprises glucose, insulin, human transferrin, selenous acid, non-essential amino acids, sodium pyruvate, ascorbate-2-phosphate, L-proline, dexamethasone, and growth factors (TGF-β1, GDF-5 and BMP-2).
4. Tissue formation: The neocartilage composition is produced using the rejuvenated cells from step 3 via “the self-assembling process,” which is a scaffold-free tissue engineering technique that seeds a high-density cell suspension in a non-adherent environment. The tissue aggregates that form during suspension culture are dissociated with trypsin and collagenase to free the cells. The liberated cells are seeded into non-adherent wells to form a neocartilage composition. The neocartilage composition is maintained in medium, e.g., a medium comprising glucose, insulin, human transferrin, selenous acid, non-essential amino acids, sodium pyruvate, ascorbate-2-phosphate, L-proline, dexamethasone, and TGF-β1 for 4-6 weeks.
5. Tissue maturation: The neocartilage composition that is formed from step 4. undergoes maturation via chondroitinase-ABC and lysyl oxidase-like 2 treatments, resulting in properties approaching native tissue values. Chondroitinase-ABC treatment is applied to temporarily reduce the glycosaminoglycan content in the matrix. This has the effect of spatially allowing for the endogenous deposition of more collagen by the seeded cells. Lysyl oxidase-like 2 is also applied to generate pyridinoline cross-links within the collagen network of the matrix. These treatments take place during the 4-6 week culture in step 4 and result in a neocartilage composition with superior mechanical properties and more mature characteristics.
For example, in some embodiments, the neocartilage composition comprises 2% glycosaminoglycan per dry weight (GAG/DW). In some embodiments, the neocartilage composition comprises ≥21% total collagen per dry weight (Col/DW). In some embodiments, the neocartilage composition exhibits ≥250 kPa tensile Young's modulus. In some embodiments, the neocartilage composition exhibits ≥10 kPa ultimate tensile strength.
Neocartilage tissue compositions described herein may be used to repair single or multiple symptomatic partial-thickness or full-thickness defects in the temporomandibular joint (TMJ) disc complex (e.g., the disc and its attachments) in adults (e.g., ages 18-65).
For example, allogeneic costal chondrocytes may be propagated in cell culture and seeded at a density of 80,000-120,000 cells/cm2. Fetal bovine serum may be used as a component of the culture medium used to propagate the allogeneic costal cells; therefore, in such cases, trace quantities of bovine-derived proteins may be present. An animal-derived reagent such as this would be purchased from Good Manufacturing Practice (GMP)-compliant manufacturers who provide an accompanying certificate of analysis. The final product is tested for viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma before use.
The neocartilage tissue composition implant is administered directly to the TMJ disc complex. The amount of neocartilage tissue composition implant administered depends on the size (e.g., area in cm2) of the defect being treated. The surgeon should trim the composition to the size and shape of the defect such that an overlap exists with the native TMG disc complex tissue once implanted. As an example, an additional 5 mm in length and 5 mm in width may be present to ensure its overlap with the native TMJ disc complex tissue once implanted.
Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in the present application is incorporated herein by reference in its entirety.
Although there has been shown and described the preferred embodiment of the present invention, it will be readily apparent to those skilled in the art that modifications may be made thereto which do not exceed the scope of the appended claims. Therefore, the scope of the invention is only to be limited by the following claims. In some embodiments, the figures presented in this patent application are drawn to scale, including the angles, ratios of dimensions, etc. In some embodiments, the figures are representative only and the claims are not limited by the dimensions of the figures. In some embodiments, descriptions of the inventions described herein using the phrase “comprising” includes embodiments that could be described as “consisting of,” and as such the written description requirement for claiming one or more embodiments of the present invention using the phrase “consisting of” is met.
This application is a continuation-in-part, and claims benefit of U.S. patent application Ser. No. 16/136,894 filed Sep. 20, 2018, which is a non-provisional application and claims benefit of U.S. Provisional Patent Application No. 62/561,105 filed Sep. 20, 2017, the specifications of which are incorporated herein in their entirety by reference.
This invention was made with government support under Grant No. R01AR067821 awarded by NIH. The government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 62561105 | Sep 2017 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16136894 | Sep 2018 | US |
| Child | 18323667 | US |
